Denver, Colo.; and Istanbul, Turkey From Plastic and Reconstructive Surgery, Denver Health Medical Center, University of Colorado Health Sciences Center; and the Department of Plastic, Reconstructive, and Aesthetic Surgery, Marmara University School of Medicine.
Plast Reconstr Surg. 2013 Aug;132(2):304-315. doi: 10.1097/PRS.0b013e31829e7d9e.
Revision breast surgery following breast augmentation secondary to capsular contracture and implant rupture is not uncommon. Breast autoaugmentation using an inferior pedicle dermoglandular flap following implant removal was used in patients who did not want new implants, and outcomes were analyzed.
Thirty-nine breasts (38 breasts bilateral, one breast unilateral) in 20 consecutive patients (aged 38 to 66 years) were operated on. Breast implant-related problems in 39 breasts included capsular contracture (grade III to IV) in 30 breasts, asymmetry in 20, implant rupture/bleed in 15, and hematoma in nine. The size of implants removed was between 250 and 525 cc. Forty-five percent of implants were saline filled and 55 percent were silicone filled. Forty percent were removed from the subglandular plane and 60 percent from the submuscular plane. A deepithelialized inferior dermoglandular flap was used to reorient breast volume along with superior or superior medial pedicle mastopexy. Reorientation of volume of the inferior flap ranged between 125 and 300 cm(3). Mean follow-up was 13.5 months.
BREAST-Q data showed improvement of satisfaction with breasts, psychosocial well-being, and sexual well-being after capsulectomy, implant removal, and autoaugmentation. There was a one-cup reduction in brassiere size in 17 patients, and the cup size remained the same in three patients. There was no evidence of fat necrosis.
The inferior dermoglandular flap along with mastopexy was a safe, reasonable, and reliable method of reorienting breast volume and configuring breast shape in this series of patients for whom implant explantation was indicated and replacement was not an option secondary to concern with reimplantation.
CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, IV.
由于包膜挛缩和假体破裂导致隆胸后需要进行乳房修复手术并不罕见。对于那些不想使用新假体的患者,我们在取出假体后使用下蒂真皮腺体皮瓣进行乳房自体增强,并对其结果进行了分析。
20 例连续患者(年龄 38 至 66 岁)共 39 只乳房(双侧 38 只,单侧 1 只)接受了手术。39 只乳房的假体相关问题包括 30 只乳房的包膜挛缩(III 至 IV 级)、20 只乳房的不对称、15 只乳房的假体破裂/出血和 9 只乳房的血肿。取出的假体大小在 250 至 525 cc 之间。45%的假体为盐水填充,55%为硅胶填充。40%从胸肌下平面取出,60%从胸肌上平面取出。使用去上皮化的下蒂真皮腺体皮瓣,与上或上内侧蒂乳房悬吊术一起重新定向乳房体积。下皮瓣体积的重新定向范围在 125 至 300 cm³之间。平均随访时间为 13.5 个月。
乳房 Q 数据显示,在包膜切除术、假体取出和自体增强后,患者对乳房的满意度、心理社会幸福感和性幸福感都有所改善。17 名患者的文胸尺寸减少了一个罩杯,3 名患者的罩杯尺寸保持不变。没有脂肪坏死的证据。
在本系列患者中,下蒂真皮腺体皮瓣联合乳房悬吊术是一种安全、合理、可靠的重新定向乳房体积和塑造乳房形状的方法,这些患者需要进行假体取出,并且由于对再次植入的担忧,不选择更换假体。
临床问题/证据水平:治疗性,IV 级。